KOSDAQBiotech & Pharma082270

GemVax & KAEL

₩11,180▼ 0.27%2026-10-02 close

Market Cap

₩507.1B

Turnover

₩1.2B

Volume

100,000 shares

Shares out.

45.5M

PER

—

PBR

5.9×

EPS

-₩277

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Filter Business Recovers as GV1001 Approval Process Advances

GemVax's clean-room filter business drove operating profit back into positive territory in 2025, but net income has remained negative for four straight years, while the bio segment's GV1001 must clear both a conditional approval review for progressive supranuclear palsy (PSP) and an Alzheimer's Phase 3 trial.

1
2025 revenue reached KRW 81.5 billion (+30.1% YoY) and operating profit turned positive at KRW 3.8 billion, yet the owner's net loss of KRW 11.3 billion marked a fourth consecutive year of net losses.
2
Over the latest five quarters (2Q2025-2Q2026) operating profit oscillated between gains and losses, and in 2Q2026 the company posted an operating profit of KRW 1.0 billion but a net loss that widened to KRW 9.9 billion.
3
Samsung Pharmaceutical filed for conditional approval of GV1001 for PSP with the MFDS in January 2026 and separately submitted a Phase 3 trial plan (204 patients, 48 weeks) in June 2026.
4
A 13-year legal dispute with Bioville was settled in April 2026, but the settlement required issuing KRW 16.3 billion in new convertible bonds and pledging the Hwaseong plant as collateral.
5
A KRW 17 billion third-party rights issue in late 2025/early 2026, followed by additional CB issuance, boosted capital but also added to potential dilution.

Business structure

GemVax operates two main business lines: an environmental pollution control segment producing chemical (CA) filters for semiconductor and display manufacturing, and a bio segment developing the telomerase-derived peptide drug candidate GV1001.

Per company disclosures, the environmental segment manufactures process filters and air-pollution control equipment for semiconductor and display fabs, while the bio segment develops GV1001-based therapeutics.

As chip and display processes move toward larger wafers and finer geometries, the application scope for chemical contamination control technology appears to be expanding across clean rooms and other industrial areas.

GV1001, a peptide licensed from Norway in 2008, was originally developed as a pancreatic cancer treatment and received conditional approval in 2014 as Korea's 21st new drug (Riavax), but that approval was later revoked after the company failed to submit Phase 3 clinical study results by 2020.

Since then, the indication scope has expanded to Alzheimer's disease, benign prostatic hyperplasia, and progressive supranuclear palsy (PSP), with domestic marketing rights for all indications except BPH held by affiliate Samsung Pharmaceutical.

GemVax and Samsung Pharmaceutical are cross-linked through shareholdings, with GemVax as Samsung Pharmaceutical's largest shareholder at a 10.46% stake, while Samsung Pharmaceutical holds 5.29% of GemVax.

In December 2025, the two companies signed a technology transfer agreement giving Samsung Pharmaceutical clinical development and commercialization rights for the PSP indication of GV1001 across four Asian markets including Korea, Japan, India, and Indonesia.

The filter business's revenue is tied to the capacity utilization and new capex plans of domestic chip and display makers, forming one of two distinct swing factors in the company's overall results alongside bio-segment clinical and regulatory events.

Earnings trend

Quarterly revenue · Operating profit

₩25B-₩1.5B25Q2₩18B₩700M25Q3₩26.2B₩7.5B25Q4₩18.3B-₩800M26Q1₩22.7B₩1B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩75.8B-₩3.9B2022₩72.2B-₩7.9B2023₩62.7B-₩38.3B2024₩81.5B₩3.8B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩25B	-₩1.5B	−6.0%
2025Q3	₩18B	₩700M	4.1%
2025Q4	₩26.2B	₩7.5B	28.7%
2026Q1	₩18.3B	-₩800M	−4.2%
2026Q2	₩22.7B	₩1B	4.4%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩75.8B	-₩3.9B	-₩19.6B	−5.2%	−14.6%	12.5%
2023	₩72.2B	-₩7.9B	-₩27.2B	−10.9%	−25.2%	25.1%
2024	₩62.7B	-₩38.3B	-₩87.2B	−61.2%	−300.7%	419.7%
2025	₩81.5B	₩3.8B	-₩11.3B	4.7%	−19.8%	177.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-22

Earnings analysis

Consolidated 2025 revenue came in at KRW 81.5 billion, up 30.1% from KRW 62.7 billion in 2024, while annual operating profit turned positive at KRW 3.8 billion, a reversal from a KRW 38.3 billion operating loss in 2024. The operating margin improved from -61.2% in 2024 to 4.7% in 2025.

However, the owner's net loss stood at KRW 11.3 billion in 2025, a marked improvement from the KRW 87.2 billion loss in 2024, but this extended a streak of net losses spanning all four years from 2022 (-KRW 19.6 billion) through 2025.

Operating cash flow turned positive at KRW 1.1 billion in 2025, contrasting with a large cash outflow of KRW 28.4 billion in 2024.

Looking at the most recent five quarters, operating profit moved from a KRW 1.5 billion loss in 2Q2025 to gains of KRW 0.7 billion and KRW 7.5 billion in 3Q and 4Q respectively, before reverting to a KRW 0.8 billion loss in 1Q2026 and a KRW 1.0 billion gain in 2Q2026, showing a pattern of repeated swings.

The net income trend is even more volatile than the operating line: in 4Q2025, when operating profit was positive, owner's net income was also positive at KRW 1.6 billion—the only positive quarter in the window—but in 2Q2026, despite another positive operating result, the net loss widened to KRW 9.9 billion.

This divergence between operating and net results points to sizable non-operating or financial items whose specific composition would require confirmation from the relevant quarterly filing footnotes.

Shareholders' equity stood at KRW 57.2 billion at end-2025, up from KRW 29.0 billion at end-2024, but still well below the KRW 134.4 billion and KRW 108.0 billion levels seen in 2022 and 2023 respectively, while the debt ratio eased to 177.6% in 2025 from 419.7% in 2024 but remains far above the 25.1% and 12.5% levels of 2023 and 2022.

Industry analysis

Demand for chemical filters and contamination-control technology used in semiconductor and display manufacturing appears to be expanding across entire clean rooms and into additional industrial applications as processes move toward larger wafers and finer geometries.

Because this business's revenue is tied to the capacity utilization and capex plans of chip and display customers, its results tend to lag the broader semiconductor cycle.

In the bio segment, progressive supranuclear palsy (PSP) remains a rare disease with no approved treatment, and GV1001 has secured designation as an orphan drug in development from the MFDS, opening a pathway to seek conditional approval based on Phase 2 results alone.

However, across Korea's pharma and biotech industry more broadly, a wave of lawsuits from investors and former executives has emerged recently, with observers noting that prolonged litigation can simultaneously undermine corporate credibility and financial stability.

GemVax itself has a precedent in which the conditional approval for Riavax was revoked after the company failed to submit Phase 3 confirmatory results, underscoring a recurring regulatory risk inherent to the conditional-approval framework, where confirmatory trial data must still be delivered after launch.

Neurodegenerative disease markets such as PSP and Alzheimer's are widely regarded as areas of significant unmet need globally, but with no approved therapies yet available domestically or abroad for these specific indications, the competitive landscape remains at an early, largely unformed stage.

Outlook

The conditional approval application for GV1001 in PSP, filed by Samsung Pharmaceutical with the MFDS in January 2026, is confirmed to still be under review.

Separately, on June 30, 2026, Samsung Pharmaceutical submitted an additional domestic Phase 3 trial plan to the MFDS, designed to evaluate efficacy and safety in 204 PSP-RS patients over 48 weeks.

For the Alzheimer's indication, a March 2024 protocol amendment reduced the target enrollment from 936 to 750 patients and simplified the dosing arm, with the company having stated a goal of completing enrollment within 2026 and submitting a final clinical study report (CSR) in 2027.

However, the planned start date for this trial has been revised six times since initial registration in 2022, so further schedule adjustments cannot be ruled out.

An earlier global Phase 2 trial of GV1001 in Alzheimer's disease reportedly missed its primary endpoint in top-line results, leaving the PSP conditional-approval outcome as the key near-term inflection point for the broader pipeline.

On the financial side, the 13-year Bioville litigation was resolved through an April 2026 settlement, removing one source of uncertainty, but the KRW 16.3 billion in newly issued convertible bonds tied to that settlement carry a put option exercisable from May 2027, meaning the company's funding capacity could again be tested around that date.

The filter business may continue contributing to revenue if customer utilization rates keep recovering, though no specific public revenue guidance from the company has been confirmed.

Valuation

PER

—

PBR

5.9×

ROE

-21.3%

EPS

-₩277

BPS

₩1,793

Dividend per share

₩0

The price-to-book ratio, whether calculated on a self-derived or KRX basis, appears to sit in a range that reflects a substantial premium over net asset value.

Earnings-based valuation metrics are difficult to establish reliably given several consecutive years of net losses and a recent pattern of quarterly results alternating between profit and loss, which leaves asset-based multiples as a relatively more usable reference point compared to earnings-based multiples.

No dividend was paid based on the most recent settlement, making dividend-related metrics similarly hard to use as a point of comparison.

While annual results show a partial shift from losses toward earnings recovery, the recurring divergence between quarterly operating profit and net income directions means that the durability of this recovery will need continued confirmation through subsequent quarterly results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-22

Bull factors

Filter Business Returns to Profit

2025 annual revenue grew 30.1% year-over-year and operating profit turned positive, indicating that recovering utilization at semiconductor and display customers is feeding through to results.

Operating profit was positive in three of the five quarters since 3Q2025, a different pattern from the entrenched losses of 2024. Operating cash flow also turned positive at KRW 1.1 billion in 2025, suggesting the earnings improvement is partly reflected in cash generation as well.

PSP Conditional Approval Process Underway

GV1001 has been designated an orphan drug in development by the MFDS, opening a pathway to seek conditional approval based on Phase 2 results alone, and Samsung Pharmaceutical formally filed that application in January 2026, with review now underway.

If approved, it would carry the symbolic weight of being Korea's first PSP treatment and would allow immediate commercialization. In parallel, a Phase 3 trial plan has also been submitted, preparing for the confirmatory trial required following any conditional approval.

Partial Resolution of Litigation Risk

The 13-year legal dispute with Bioville was resolved through an April 2026 settlement, removing the uncertainty tied to a potential Supreme Court ruling and the associated enforcement risk.

The settlement also cleared much of the KRW 29.5 billion held in court escrow, resolving the uncertainty around those tied-up funds. The company stated the decision was aimed at eliminating the risk of prolonged litigation and allowing it to focus on its core drug development business.

Bear factors

Four Straight Years of Net Losses

Owner's net income was negative in every year from 2022 through 2025, with a KRW 11.3 billion net loss recorded again in 2025.

Even in quarters with positive operating profit, net income has swung to large losses (KRW -9.9 billion in 2Q2026), suggesting non-operating factors are adding significant volatility to results. Shareholders' equity stood at KRW 57.2 billion at end-2025, less than half the levels seen in 2022-2023.

Repeated Fundraising and CB Burden

Following a KRW 17 billion third-party rights issue at the end of 2025, an additional KRW 16.3 billion in convertible bonds was issued in April 2026 to fulfill the litigation settlement.

These CBs carry a put option exercisable from May 2027, leaving open the possibility that the company will need to redeem them in cash if the share price stays below the conversion price. The pledging of the Hwaseong plant as settlement collateral is an additional constraint on financial flexibility.

Track Record of Pipeline Delays

The planned start date for GV1001's Alzheimer's Phase 3 trial has been revised six times since its 2022 registration, repeatedly underscoring low predictability in the clinical timeline. An earlier global Phase 2 trial in Alzheimer's disease has already reported top-line results that missed the primary endpoint.

Riavax, GV1001's earlier pancreatic cancer indication, had its conditional approval revoked after the company failed to submit Phase 3 results, and a similar risk persists for the PSP indication.

Risk factors

Regulatory & Clinical

The outcome of the PSP conditional approval review remains unresolved, and even if approved, it would come with a requirement to submit confirmatory Phase 3 results. As with the earlier Riavax case, a delayed or failed Phase 3 submission could lead to revocation of approval.

The Alzheimer's indication has a history of missing its primary endpoint in a global Phase 2 trial, leaving Phase 3 success uncertain as well.

Financial & Liquidity

While the debt ratio has improved from 2024 levels, it remains elevated compared with 2022-2023, and the capital structure continues to shift with repeated rights issues and CB issuances. A CB put option exercisable from May 2027 could translate into future cash demands on the company.

Given the large quarter-to-quarter swings in net income, the stability of future cash generation will require continued monitoring.

Governance

The largest shareholder, Gem & Company, has reportedly been in a state of capital impairment, raising the possibility that the controlling shareholder's financial condition could affect the stability of the company's governance.

Even after the founder resigned from the board, control has reportedly been maintained through affiliated entities, a structure that has previously given rise to multiple lawsuits over fund and equity transfers among group companies.

The cross-shareholding structure with Samsung Pharmaceutical also remains a point requiring alignment of interests between the two companies.

What to watch next

Around November 2026 (expected 3Q report filing)
When the 3Q2026 results are disclosed, it will be possible to check whether the recent divergence between operating and net income persists and whether the filter business's utilization recovery continues.
Second half of 2026 (upon MFDS conditional approval decision)
Once the MFDS announces its decision on GV1001's PSP conditional approval, it will be a key event to confirm whether Korea's first PSP treatment is approved and when commercialization could begin.
By end-2026 (company's stated target)
It is worth checking whether the company meets its stated target of completing enrollment of 750 Alzheimer's Phase 3 patients by year-end, as a gauge of the feasibility of its 2027 CSR submission goal.
Second half of 2026 (PSP Phase 3 trial plan review outcome)
The outcome of the MFDS review of the PSP Phase 3 trial plan (204 patients, 48 weeks) submitted on June 30, 2026 should be confirmed.
Around May 6, 2027
This marks the start date for the put option on CBs issued as part of the Bioville settlement, a point at which the company's cash readiness merits scrutiny in advance.

Overall view

GemVax is a company where two distinct dynamics are unfolding simultaneously: a recovery in revenue and operating profit at its core semiconductor filter business, and ongoing regulatory progress for its GV1001-centered bio pipeline.

Full-year 2025 results showed revenue growth and a return to operating profit, but net income remained negative for a fourth consecutive year, and recent quarters have repeatedly shown operating profit and net income moving in opposite directions.

In the bio segment, the PSP conditional approval review is underway, carrying the possibility of becoming Korea's first approval of its kind, while also bearing the regulatory risk inherent in the conditional-approval framework, as illustrated by the earlier revocation of the Riavax approval.

Financially, the resolution of the 13-year Bioville litigation through settlement cleared one source of uncertainty, but the convertible bonds, put option, and repeated rights issues that accompanied it leave the company's future funding capacity as a point warranting continued observation.

The Alzheimer's Phase 3 trial has a history of repeated schedule delays, so whether its stated timeline target is met remains to be seen.

For observers, it will be important to track the filter business's performance in line with the semiconductor cycle, regulatory and clinical events surrounding GV1001, and how the capital structure evolves following the litigation settlement.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.